Holdings
Select Biotechnology Portfolio
As of May 31, 2026, Select Biotechnology Portfolio reported 161 positions worth US$5.12B. Largest: Krystal Biotech, Inc., Abbvie Inc. and Amgen Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Krystal Biotech, Inc. | 1.8M | US$557M | −3,900 | May 31, 2026 |
| Abbvie Inc. | 2.23M | US$486M | −819K | May 31, 2026 |
| Amgen Inc. | 1.02M | US$344M | −129K | May 31, 2026 |
| Gilead Sciences, Inc. | 1.89M | US$254M | −1.26M | May 31, 2026 |
| Alnylam Pharmaceuticals, Inc. | 512K | US$155M | +15,000 | May 31, 2026 |
| Praxis Precision Medicines, Inc. | 371K | US$130M | −19,071 | May 31, 2026 |
| Insmed Incorporated | 1.11M | US$119M | +298K | May 31, 2026 |
| Argenx Se | 141K | US$118M | −7,900 | May 31, 2026 |
| Ascendis Pharma A/s | 480K | US$108M | −77,800 | May 31, 2026 |
| Revolution Medicines, Inc. | 675K | US$106M | +236K | May 31, 2026 |